Ben Wylie, senior product manager at ChargePoint Technology explains how single use technologies can help pharmaceutical manufacturers during bioprocessing.
Hybrid
The global single use bioprocessing market was valued at USD 9.71 billion in 2017 and is projected to expand at a CAGR of 13.6% by 2027. A rise in demand for small batch, novel therapies is in turn leading to an increased need for vigorous and flexible containment strategies to ensure product sterility during bioprocessing. Consequently, the technologies used in aseptic processing have seen much innovation in recent years but it’s important for such solutions to also achieve cost reductions, process efficiencies and improved quality in line with industry regulations.
The growth of the bioprocessing market is also fuelling the booming contract services space. Much of the development, manufacturing and packaging of products is completely outsourced. While supporting the development of novel biologics, this can bring added complexity to the manufacturing journey, as drug products often need to be transferred between different facilities and geographies.